Hintringer, K. (2010): Panitumumab (Vectibix ®) for the first-line treatment of metastatic colorectal cancer. DSD: Horizon Scanning in Oncology 11.
|PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader|
Despite data indicating that patients suffering from metastatic colorectal cancer with wild-type KRAS status might benefit from first-line therapy with panitumumab, several unresolved issues make it difficult to judge its final clinical value. Phase III trials demonstrated superiority of adding panitumumab to standard of care vs. standard of care alone for the surrogate endpoint progression free survival. Therefore, regulatory authorities approved panitumumab for the 1st-line treatment of mCRC linked to the condition of further assessments incorporating patient relevant outcomes such as quality of life and overall survival.
|Item Type:||DSD: Horizon Scanning in Oncology|
|Keywords:||metastatic colorectal cancer, mCRC, panitumumab, Vectibix, oncology|
|Subjects:||WB Practice of medicine > WB 300-962 Therapeutics|
QZ Pathology > QZ 200-380 Neoplasms.Cysts
WI Digestive system > WI 400-560 Intestines
QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology
|Series Name:||DSD: Horizon Scanning in Oncology 11|
|Deposited on:||14 Jul 2010 12:22|
|Last Modified:||14 Jul 2010 12:22|
Repository Staff Only: item control page